Sotorasib

Active Ingredient: Sotorasib
Form: Oral tablet
Brand Name: Lumakras
Generic Name: Sotakras
Generic Manufacturer: Ziska Pharmaceuticals

Indications:
Lumakras is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy.

Dosage and Administration:
The recommended dose is 960 mg orally once daily, either as a single dose or divided into two doses. It should be taken at the same time each day, with or without food.

• If a dose is missed by more than 6 hours, skip it and resume the regular dosing schedule.

• If vomiting occurs after taking a dose, do not take an additional dose.

Common Side Effects:
Serious adverse effects include hepatotoxicity and interstitial lung disease (ILD). Signs may include elevated liver enzymes or bilirubin, cough, shortness of breath, and fever. If symptoms occur, seek medical attention and adjust treatment accordingly.

Storage:
Store below 25°C in a cool, dry place away from light. Keep out of reach of children.

Frequently Asked Questions

Q: What is the relationship between Lumakras and Sotorasib?
A: Lumakras is the brand name registered by the original manufacturer. Sotorasib is its active ingredient.

Q: Is the Lumakras sold by Mediva Rx the original brand-name drug?
A: No. Mediva Rx offers a high-quality generic version manufactured by one of Bangladesh’s top 10 pharmaceutical companies. It contains the same active ingredient and therapeutic efficacy as the original and is tested and approved by the Directorate General of Drug Administration (DGDA).

Q: Is the manufacturer of the Lumakras generic reliable?
A: Yes. We work with Ziska Pharmaceuticals, a leading pharmaceutical company in Bangladesh with certified in-house R&D, manufacturing, and quality control labs. They are internationally certified for Good Manufacturing Practice (GMP). You can purchase with confidence.

Q: What is the target of Lumakras and who is it suitable for?
A: Lumakras targets KRAS G12C mutations. It is specifically suitable for NSCLC patients who have this mutation. If your cancer does not involve a KRAS mutation, refer to our “NSCLC Targeted Therapy Guide” to explore alternative treatment options.

Disclaimer:
This information is for reference only. Always consult your physician for medical advice and refer to the official prescribing information and latest clinical research before starting or modifying any treatment.

Drug Instructions (Package Insert):
Download Link